FDA Hands Fast-Pass Voucher to Rare Disease Kid Drug Maker
Published Date: 2/18/2026
Notice
Summary
The FDA just gave a special priority review voucher to Abeona Therapeutics for their rare pediatric disease treatment, ZEVASKYN, approved in April 2025. This voucher speeds up future drug reviews, helping get important medicines to patients faster. It’s a big win for kids with rare diseases and could save time and money in bringing new treatments to market.
No Economic Impacts Identified for this Document
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in